

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

Global Wholehealth Partners Corporation

A Nevada Corporation

2227 Avenida Oliva
San Clemente, California 92673
Phone: (714) 392-4112
Website: [http:// WWW.GlobalWholeHealthPartnersCorp.COM](http://WWW.GlobalWholeHealthPartnersCorp.COM)
Email: cstrongo@gmail.com
SIC Code: 1382

Annual Report
For the Year Ending: June 30, 2019
(the “Reporting Period”)

As of June 30, 2019, the number of shares outstanding of our Common Stock was:

56,116,358

As of March 31, 2019, the number of shares outstanding of our Common Stock was:

52,538

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company’s shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Indicate by check mark whether a Change in Control of the company has occurred over this reporting period:

Yes: ☐ No: ☒

ITEM 1 NAME OF ISSUER AND ITS PREDECESSORS (if any):

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

The Company was originally incorporated in the State of Nevada on March 7, 2013 as Texas Jack Oil & Gas Corporation. On May 20, 2019, the Company changed its name to Global Wholehealth Partners Corporation.

Date and state (or jurisdiction) of incorporation (also describe any changes to incorporation since inception, if applicable) **March 7, 2013 - Nevada**

Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive): **Active**

Has the issuer or any of its predecessors ever been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐ No: ☒

ITEM 2 SECURITY INFORMATION:

Trading symbol: **GWHP**

Exact title and class of securities outstanding: **Common stock**

CUSIP: **37959N102**

Par or stated value: **\$0.001**

Total shares authorized: **400,000,000 shares** as of date: **June 30, 2019**

Total shares outstanding: **56,116,358 shares** as of **June 30, 2019**

Number of shares in the Public Float: **10,502,000** as of **June 30, 2019**

Additional Classes:

Trading symbol: **None**

Exact title and class of securities outstanding: **None**

CUSIP: **None**

Par or stated value: **None.**

Total shares authorized: **None** as of date: **June 30, 2019**

Total shares outstanding: **None** as of **June 30, 2019**

Transfer Agent:

Name: **Globex Transfer, LLC**

Phone: **813-344-4490**

Email: **mt@globextransfer.com**

Is the Transfer Agent registered under the Exchange Act? Yes: ☒ No: ☐

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors: **None.**

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

On May 9, 2019, pursuant to board of directors approval and majority shareholder consent, the Company filed a certificate of amendment to its articles of incorporation with the State of Nevada to change the name of the corporation from Texas Jack Oil & Gas Corporation to Global Wholehealth Partners Corporation (the "Name Change") and a Certificate of Change with the State of Nevada effectuating a one (1) for five hundred (500) reverse stock split of the Company's outstanding Common Stock to which every five hundred (500) shares of outstanding Common Stock of the Company shall be converted into one (1) share of Common Stock (the "Reverse Stock Split"). As a result of the Reverse Stock Split, each five hundred (500) shares of Common Stock issued and outstanding prior to the Reverse Stock Split has been converted into one (1) share of Common Stock. The Company will not issue fractional shares in connection with the Reverse Stock Split. Fractional shares will be rounded up to the nearest whole share. The Name Change and Reverse Stock Split was announced on the Daily List maintained by Financial Industry Regulatory Authority on May 17, 2019 and took effect at the open of business on May 20, 2019.

ITEM 3 ISSUANCE HISTORY

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☐

Number of Shares outstanding as of July 1, 2017	Opening Balance: Common: 52,358								
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) OR Nature of Services Provided (if applicable)	Restricted or Unrestricted as of this filing?	Exemption or Registration Type?
4/28/2019	New issuance	64,000(1)	Common	\$.001	Yes	Barbara Bauman	Debt conversion and consulting services	Restricted	Section 4a2
6/27/2019	New Issuance	56,000,000(2)	Common	\$.001	Yes	Lionsgate Funding Group LLC/Sara Gonzales	Pursuant to stock purchase agreement	Restricted	Section 4a2
Shares Outstanding on June 30, 2019	Ending Balance: Common: 56,116,358								

- (1) On May 2, 2019, Barbara McIntyre Bauman, the majority shareholder of Company, entered into a Stock Purchase Agreement with LionsGate Funding Group LLC, Sara Gonzales control person, to purchase the 64,000 shares of common stock. outstanding shares of common stock.
- (2) May 23, 2019, the Company and LionsGate Funding Group LLC (“LionsGate”), owner of a majority of the Company’s outstanding common stock as of May 23, 2019, entered into a Stock Sale and Purchase Agreement (the “SPA”) which closed on June 27, 2019. Pursuant the SPA, the Company issued 56,000,000 shares of common stock to LionsGate in exchange for 100% of their interests in Global WholeHealth Partners Corp., a private Wyoming corporation incorporated on April 9, 2019 (“Global Private”).

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe any issuance of promissory notes, convertible notes or convertible debentures in the past two completed fiscal years and any subsequent interim period.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ☒

ITEM 4 FINANCIAL STATEMENTS

- A. The Annual Report, for the year ended June 30, 2019 posted to OTCIQ on October 11, 2019 were prepared in accordance with:

☒ U.S. GAAP
☐ IFRS

- B. The financial statements for this reporting period were prepared by (name of individual):

Name: **Richard Johnson**
Title: **Chief Financial Officer**
Relationship to Issuer: **Chief Financial Officer**

The required financial statements are incorporated by reference to:
Annual Report, for the year ended June 30, 2019 posted to OTCIQ on October 11, 2019.

ITEM 5 ISSUER’S BUSINESS, PRODUCTS AND SERVICES

A. Summarize the issuer’s business operations:

Global WholeHealth Partners, Corp., (“Global WholeHealth Partners,” “GWHP,” or the “Company”), Company’s executive offices are located in San Clemente, California with manufacturing, warehousing and laboratories in San Diego and Oceanside California.

The Company was founded to develop, manufacture and market in vitro diagnostic (IVD) tests for over-the-counter (OTC or consumer), and point-of-care (POC or professional) use markets. The Company currently manufactures and markets a range of diagnostic test kits for consumer use through over-the-counter (OTC) sales, and for use by health care professionals, generally located at medical clinics, physician offices and hospitals known as Points-of-Care (POC), in the United States. These test kits are known as in vitro diagnostic test kits or “IVD” products.

GWHP has evolved into a leading Health Care company by expanding itself from diagnostic products to the full service health care company. GWHP has partnered with several companies in the health care industry which broaden the scope of GWHP business, giving GWHP a strong controlling vertical and horizontal integration in the health care industry.

B. Describe any subsidiaries, parents, or affiliated companies, if applicable, and a description of their business contact information for the business, officers, directors, managers or control persons. Subsidiary information may be included by reference: None.

C. Describe the issuers’ principal products or services, and their markets:

The Company was founded to develop, manufacture and market in vitro diagnostic (IVD) tests for over-the-counter (OTC or consumer), and point-of-care (POC or professional) use markets. The Company currently manufactures and markets a range of diagnostic test kits for consumer use through over-the-counter (OTC) sales, and for use by health care professionals, generally located at medical clinics, physician offices and hospitals known as Points-of-Care (POC), in the United States. These test kits are known as in vitro diagnostic test kits or “IVD” products.

GWHP has evolved into a leading Health Care company by expanding itself from diagnostic products to the full service health care company. GWHP has partnered with several companies in the health care industry which broaden the scope of GWHP business, giving GWHP a strong controlling vertical and horizontal integration in the health care industry.

ITEM 6 ISSUER’S FACILITIES

The Company has no facilities to list.

ITEM 7 OFFICER, DIRECTORS AND CONTROL PERSONS

DIRECTORS AND EXECUTIVE OFFICERS

The following table sets forth the names and ages of all of our directors and executive officers as of the date of this report. We have a Board comprised of two members. Each director holds office until a successor is duly elected or appointed. Executive officers serve at the discretion of the Board and are appointed by the Board. Also provided herein are brief descriptions of the business experience of each of the directors and officers during the past five years, and an indication of directorships held by each

director in other companies subject to the reporting requirements under the Federal securities law.

Name	Age	Current Position With Us	Director or Officer Since
Charles Strongo	55	CEO, President and Chairman	August 1, 2019
Richard Johnson	85	CFO, Treasurer and Director	August 1, 2019
Sara P. Gonzales	46	Secretary	May 6, 2019
Rene Alvarez	81	Director	August 1, 2019
Dr. Scott Ford	66	Director	August 1, 2019
Dr. Shuijie Cui	55	Chief Science Officer and Director	August 1, 2019
Wolfgang Groeters	84	Director	August 1, 2019

Biographical Information

Set forth below are the names of all of our directors and executive officers, all positions and offices held by each person, the period during which each has served as such, and the principal occupations and employment of such persons during at least the last five years, and other director positions held currently or during the last five years:

Current Directors and Officers

Charles Strongo, MBA. Mr. Strongo has 30 years' experience in business management and operations with a proven track record of increasing profitability in the health care industry and particularly in the in-vitro diagnostic industry. Mr. Strongo has been in the in vitro diagnostic business for the past Twenty-Four years, having begun in 1995, the beginning of the "over-the counter" in-vitro diagnostic industry and has managed annual budgets exceeding \$500 million. Mr. Strongo has served as President and Chief Executive Officer of EarlyDETECT, Inc. (EDI) since March, 2004. He was a member of the EDI Board of Directors from June 2002 until June 2009. Prior to that, Mr. Strongo served as the Chief Financial Officer for two years. Mr Strongo has owned and operated his own successful FDA Approved diagnostic manufacturing facility. Mr. Strongo has a comprehensive knowledge of ISO and FDA regulations and has prepared several companies for the ISO inspections. Mr. Strongo has filed more than twenty FDA 510K filings; he has also worked on countless pharmaceutical filings. Mr. Strongo has prepared several companies for FDA inspections, under FDA regulatory GMP guidelines. Mr. Strongo has cleared companies for ISO 13485 CDM in less than 6 months, a process that usually takes a year. Mr. Strongo's dynamic personality, keen understanding and extensive professional expertise, have enabled Mr. Strongo to increase profitability for multiple companies domestically and internationally. Mr. Strongo established businesses in foreign countries, including Canada, Brazil, China, South Africa, Russia, Taiwan, Mexico, Malaysia, Thailand, and the Philippines. Mr. Strongo holds a BA/MBA in Business Management from National University.

Richard Johnson. Mr. Johnson brings a wealth of experience at the senior executive levels in the areas of Corporate Finance, Business Planning & Operations, R&D and Administration. His considerable strengths in the areas of Finance and Corporate Administration will greatly assist the Company as it advances towards production. Mr. Johnson's enviable record of achievements at the executive level includes, CFO at Early Detect Inc. where he supervised the financial activities of the Company and its subsidiaries over a span of 4.5 years. Previously, he held positions of Chief Financial Officer, General Manager and Director in industry and also was a Senior Management and Finance Consultant to the manufacturing, retail, agriculture and service industries for fifteen years as well as Program Control Director and Management Consultant with a major international Engineering and Construction Corporation. Early in his career, Mr. Johnson spent eleven years with the U.S. Department of Energy, Las Vegas, where he had the responsibilities of financial analysis, budgeting and Safety analysis in the areas of nuclear explosives internationally. Since 2010, Mr. Johnson has served as Chief Financial Officer and Director of WholeHealth Products, Inc. and Chief Financial Officer of Arizona Gold and Onyx Mining Co.

Sara P. Gonzales. Sarah has been in the in-vitro diagnostic industry working as a chief administrator for over 15 years with experience at EarlyDetect and Sharp Memorial Hospital. Sarah has worked in Human Resources and as Director of Business Development. Recently, Sarah has moved to Nunzia Pharmaceutical as the President and has co-founded a nonprofit for people with an Autistic Spectrum Disorder, such as Autism, ADD/ADHD, OCD, and PTSD. Sarah is the Vice President and Co-Founder of Autism Fragile X Foundation. Sara has a great understanding of business development and progress. She has an exemplarily ability to motivate and encourage people to do their best. Sarah has become the director of new business development for Global WholeHealth Partners Corp. Sarah's contacts in Mexico and other countries have been and will be a tremendous asset to Global WholeHealth Partners Corp.

Rene Alvarez. Mr. Alvarez is a graduate of Canisius College (BS in Accounting) and earned a law degree at the State University of New York at Buffalo (LLB and JD degrees). He was admitted to the New York State Bar Association in 1969. Mr. Alvarez also

spent two years in the U.S. Army where he attained the rank of Captain and earned the Bronze Star while serving in Viet Nam. After fulfilling his military service, he joined Ford Motor Company in 1969 where he held various key executive positions including Senior Vice President of a Ford subsidiary from which he retired in 1999. After retiring, Mr. Alvarez joined LA Fitness International, LLC as Corporate Vice President until he once again retired in June of 2011. Mr. Alvarez also served as Chairman of the Board of L. L. Knickerbocker Company, a major marketing and distribution source for celebrity products and currently serves on the Boards of Planet Electric, Inc., Whole Health Product, Inc., Las Vegas Cares, and Nevco Co. Mr. Alvarez resides in Newport Beach, California with his wife and two children.

Dr. Scott Ford. Dr. Ford practiced general dentistry for over 39 years retiring in 2016. Dr. Ford taught at USC Dental School as a clinical instructor, part-time for over 7 years both in Emergency Dentistry and Restorative Dentistry. Dr. Ford was a co-founder of Rowpar Pharmaceuticals, a privately held dental products corporation and manufacturer of ClōSYS® oral health products. Dr. Ford received his BA in Biology from UC San Diego in 1975 and DDS degree from University of Southern California School Of Dentistry in 1971.

Shuijie Cui. Mr. Cui served as a post doctorate Fellow in the Ob/Gyn and Reproductive Biology department of The University of Texas Medical School at Houston. Mr. Cui also served as a post doctorate Fellow in the Division of Laboratory Medicine, M.D. Anderson Cancer Center at The University of Texas, Houston. Dr. Cui is known as the father of Strep A Tests. Dr. Cui worked with the Chinese Government on the testing and vaccine for SARS. Dr.

Wolfgang Groeters. Mr. Groeters' brings several decades of experience in health care and diagnostics and had worked as an engineer for Medtronic's, Bentley Labs, Edward Science and others. Wolfgang has a strong understanding of the health care industry in specialty items.

All of our directors are elected annually to serve for one year or until their successors are duly elected and qualified.

Using the tabular format below, please provide information regarding any person or entity owning 5% or more of the issuer, as well as any officer, and any director of the company, regardless of the number of shares they own. **If any listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information of an individual representing the corporation or entity in the note section.**

Name of Officer/Director and Control Person	Affiliation with Company (e.g. Officer/Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding(1)	Note
Charles Strongo	CEO, President and Chairman	San Clemente, CA	8,325,531	Common	14.84%	None
Sara P. Gonzales	Secretary	San Clemente, CA	3,750,000	Common	6.68%	None
Richard Johnson	CFO, Treasurer and Director	Brea, CA	4,840,000	Common	8.62%	None
Dr. Shuijie Cui	Chief Science Officer and Director	San Diego, CA	2,775,000	Common	4.95%	None
Dr. Scott Ford	Director	Huntington Beach, CA	417,334(2)	Common	Less than 1%	None
Rene Alvarez	Director	Newport Beach, CA	6,538,666	Common	11.65%	None
Wolfgang Groeters	Director	Tustin, CA	2,030,000	Common	3.62%	None
Lionsgate Funding Group/Control person of shares Sara Gonzales	More than 5%	San Clemente, CA	3,714,700	Common	6.62%	None

- 1) Calculated on the basis of 56,116,358 shares of common stock outstanding as of October 11, 2019.
- 2) 409,834 shares held in Scott Alan Ford TTEE Scott A Ford Family Trust and 7,500 shares held in Scott Ford & Julie Ford TTEES, Scott Ford and Julie Ford Family Trust.

ITEM 8 LEGAL/DISCIPLINARY HISTORY

A. Please identify whether any of the persons listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None.

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None.

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None.

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None.

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities. **None.**

ITEM 9 THIRD PARTY PROVIDERS:

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name:

Firm:

Address 1:

Address 2:

Phone:

Email:

Accountant or Auditor

BF Borgers CPA PC

Accounting/Auditing Firm

5400 West Cedar Avenue

Lakewood, CO 80226

303-257-9003

Investor Relations Consultant

None.

Other Service Providers

None.

ITEM 10 ISSUER CERTIFICATION

I, Charles Strongo, certify that:

1. I have reviewed this Annual Report of Global Wholehealth Partners Corporation;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: October 11, 2019

/s/ Charles Strongo

Charles Strongo
Chief Executive Officer
(Principal Executive Officer)

I, Richard Johnson, certify that:

1. I have reviewed this Annual Report of Global Wholehealth Partners Corporation;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: October 11, 2019

/s/ Richard Johnson

Richard Johnson
Chief Financial Officer
(Principal Financial Officer)